Drug Trial Radar · NCT07496229
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Apr 15, 2026
Primary completion
Sep 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.
Conditions
- T-cell Lymphomas
Interventions
GW5282 combined with GolidocitinibDrug
GW5282 and Golidocitinib will be administered in combination as twice daily (BID) and once daily (QD), respectively. The starting dose will be GW5282 40 mg BID combined with golidocitinib 150 mg QD. If tolerated, the dose of GW5282 will be subsequently escalated.
GW5282 combined with GolidocitinibDrug
GW5282 and Golidocitinib will be administered at the doses determined during escalation part.
Conventional CHOP regimenDrug
CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
GW5282 combined with GolidocitinibDrug
GW5282 and Golidocitinib will be administered at the doses determined during escalation part.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).Time frame: The DLT observation period is defined as the 21 days after the first dose.
- Part B: Complete Response Rate (CRR) According to Lugano 2014 by Investigators' ReviewTime frame: Up to 6 cycles, each cycle is 21 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, China · Not yet recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.